secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0000950170-24-023083
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology reports Q4 net loss $88.1M; cash $205M; raises $190M in Feb; 40-60 patients in 2024
--------------------------------------------------------------------------------

- Q4 2023 net loss $88.1M ($0.45/share); full year net loss $283.3M ($1.46/share).
- Cash $205.2M at Dec 31, 2023; Feb 2024 offering raised $189.8M gross proceeds to fund pipeline.
- Plans to treat 40-60 patients in 2024 across 4 trials in oncology, autoimmune, and type 1 diabetes.
- Early SC291 data safe, immune evasion, early efficacy; IND cleared for SC291 in autoimmune and SC262 in B-cell malignancies.
- Appointed Doug Williams President R&D, Gary Meininger CMO; expects 2024 operating burn <$200M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024023083/0000950170-24-023083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000095017024023083/sana-20240229.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-023083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer